To clarify whether silencing of DNAJA1 could be beneficial in the treatment of cancer, we screened wildtype HAP1 cells and HAP1 cells lacking DNAJA1 (HAP1DNAJA1 KO) for comparative resistance against the NIH NCI Approved Oncology Collection (Fig. 2A) (https://dtp.cancer.gov/organization/dscb/obtaining/available_plates.html). This evidence concerns the gene DNAJA1 and cancer.